Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V W-S Wong

Showing results (1-10 of 165) with videos related to

Pageof 17
Sort By:
Alimentary Pharmacology & Therapeutics|July 4, 2012
Commentary: new tools to assess hepatic steatosis--what do we want to measure?Z Yu, V W-S Wong
Alimentary Pharmacology & Therapeutics|December 21, 2012
Commentary: assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers--authors' replyJ Shen, V W-S Wong
Alimentary Pharmacology & Therapeutics|December 21, 2012
Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis--authors' replyJ Shen, V W-S Wong
Alimentary Pharmacology & Therapeutics|April 5, 2013
Commentary: non-alcoholic fatty pancreas -- toward an uncharted territoryR Kwok, V W-S Wong
Alimentary Pharmacology & Therapeutics|May 23, 2014
Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-viralsV W-S Wong, C-J Liu
Alimentary Pharmacology & Therapeutics|June 18, 2011
Is liver stiffness measurement unreliable in obese patients?V W-S Wong, H L-Y Chan
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|March 9, 2022
Dynamic change of LSM-HCC score and enhanced liver fibrosis score to predict hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral treatment: abridged secondary publicationG L H Wong, V W S Wong
Alimentary Pharmacology & Therapeutics|September 17, 2016
Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? Authors' replyG L-H Wong, V W-S Wong
Alimentary Pharmacology & Therapeutics|October 4, 2016
Letter: is HIV infection an important factor for liver fibrosis? Authors' replyG Lui, V W-S Wong, N Lee
Alimentary Pharmacology & Therapeutics|December 22, 2017
Editorial: non-alcoholic fatty liver disease-it is better to be slender after allJ C-F Leung, V W-S Wong
Pageof 17

Showing results (1-10 of 165) with videos related to

Sort By:
Pageof 17
Alimentary Pharmacology & Therapeutics|July 4, 2012
Commentary: new tools to assess hepatic steatosis--what do we want to measure?Z Yu, V W-S Wong
Alimentary Pharmacology & Therapeutics|December 21, 2012
Commentary: assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers--authors' replyJ Shen, V W-S Wong
Alimentary Pharmacology & Therapeutics|December 21, 2012
Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis--authors' replyJ Shen, V W-S Wong
Alimentary Pharmacology & Therapeutics|April 5, 2013
Commentary: non-alcoholic fatty pancreas -- toward an uncharted territoryR Kwok, V W-S Wong
Alimentary Pharmacology & Therapeutics|May 23, 2014
Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-viralsV W-S Wong, C-J Liu
Alimentary Pharmacology & Therapeutics|June 18, 2011
Is liver stiffness measurement unreliable in obese patients?V W-S Wong, H L-Y Chan
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|March 9, 2022
Dynamic change of LSM-HCC score and enhanced liver fibrosis score to predict hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral treatment: abridged secondary publicationG L H Wong, V W S Wong
Alimentary Pharmacology & Therapeutics|September 17, 2016
Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? Authors' replyG L-H Wong, V W-S Wong
Alimentary Pharmacology & Therapeutics|October 4, 2016
Letter: is HIV infection an important factor for liver fibrosis? Authors' replyG Lui, V W-S Wong, N Lee
Alimentary Pharmacology & Therapeutics|December 22, 2017
Editorial: non-alcoholic fatty liver disease-it is better to be slender after allJ C-F Leung, V W-S Wong
Pageof 17